Skip to Main Content

CHICAGO – For José Baselga, who took over cancer research and development at AstraZeneca after leaving a top job at Memorial Sloan Kettering under a cloud, new data the company is presenting Sunday morning about using its drug Lynparza in pancreatic cancer are a vindication.

“It’s unbelievable,” said Baselga. “It validates the principle we have been fighting for all these years: that even in the most difficult disease, even the disease where you think you’re not going to win, if you find the genetic vulnerability, if you find that, then those giants, they crumble.”

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!


Comments are closed.